Is XENE or AVBP more profitable?

Xenon Pharmaceuticals' return on equity of -43.98% beat ArriVent BioPharma's return on equity. Company Net Margins Return on Equity Return on Assets Xenon Pharmaceuticals N/A -43.98% -41.72% ArriVent BioPharma N/A -50.26% -46.66%

Does the media refer more to XENE or AVBP?

In the previous week, Xenon Pharmaceuticals had 12 more articles in the media than ArriVent BioPharma. MarketBeat recorded 17 mentions for Xenon Pharmaceuticals and 5 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 1.46 beat Xenon Pharmaceuticals' score of 1.34 indicating that ArriVent BioPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xenon Pharmaceuticals 14 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ArriVent BioPharma 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media prefer AVBP or PTCT?

In the previous week, PTC Therapeutics had 5 more articles in the media than ArriVent BioPharma. MarketBeat recorded 10 mentions for PTC Therapeutics and 5 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 1.46 beat PTC Therapeutics' score of 1.15 indicating that ArriVent BioPharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ArriVent BioPharma 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive PTC Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AVBP or DNTH?

In the previous week, Dianthus Therapeutics had 5 more articles in the media than ArriVent BioPharma. MarketBeat recorded 10 mentions for Dianthus Therapeutics and 5 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 1.46 beat Dianthus Therapeutics' score of 1.34 indicating that ArriVent BioPharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ArriVent BioPharma 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Dianthus Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to LGND or AVBP?

In the previous week, ArriVent BioPharma had 2 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 5 mentions for ArriVent BioPharma and 3 mentions for Ligand Pharmaceuticals. ArriVent BioPharma's average media sentiment score of 1.46 beat Ligand Pharmaceuticals' score of 0.90 indicating that ArriVent BioPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ligand Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ArriVent BioPharma 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media favor CRSP or AVBP?

In the previous week, CRISPR Therapeutics had 8 more articles in the media than ArriVent BioPharma. MarketBeat recorded 13 mentions for CRISPR Therapeutics and 5 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 1.46 beat CRISPR Therapeutics' score of 0.36 indicating that ArriVent BioPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 1 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral ArriVent BioPharma 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

ArriVent BioPharma (AVBP) Competitors

$30.37 -0.14 (-0.46%)

As of 03:39 PM Eastern

Compare

AVBP vs. XENE, PTCT, DNTH, LGND, and CRSP

Should you buy ArriVent BioPharma stock or one of its competitors? ArriVent BioPharma's main competitors and comparable companies include Xenon Pharmaceuticals (XENE), PTC Therapeutics (PTCT), Dianthus Therapeutics (DNTH), Ligand Pharmaceuticals (LGND), and CRISPR Therapeutics (CRSP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does ArriVent BioPharma compare to Xenon Pharmaceuticals?

Xenon Pharmaceuticals (NASDAQ:XENE) and ArriVent BioPharma (NASDAQ:AVBP) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings.

95.5% of Xenon Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are owned by institutional investors. 2.9% of Xenon Pharmaceuticals shares are owned by insiders. Comparatively, 8.6% of ArriVent BioPharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Xenon Pharmaceuticals has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market. Comparatively, ArriVent BioPharma has a beta of 1.35, meaning that its share price is 35% more volatile than the broader market.

In the previous week, Xenon Pharmaceuticals had 12 more articles in the media than ArriVent BioPharma. MarketBeat recorded 17 mentions for Xenon Pharmaceuticals and 5 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 1.46 beat Xenon Pharmaceuticals' score of 1.34 indicating that ArriVent BioPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xenon Pharmaceuticals	14 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ArriVent BioPharma	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Xenon Pharmaceuticals presently has a consensus target price of $77.13, indicating a potential upside of 27.92%. ArriVent BioPharma has a consensus target price of $44.86, indicating a potential upside of 47.07%. Given ArriVent BioPharma's higher possible upside, analysts plainly believe ArriVent BioPharma is more favorable than Xenon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

ArriVent BioPharma has lower revenue, but higher earnings than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenon Pharmaceuticals	$7.50M	777.23	-$345.91M	-$4.74	N/A
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.62	N/A

Xenon Pharmaceuticals' return on equity of -43.98% beat ArriVent BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xenon Pharmaceuticals	N/A	-43.98%	-41.72%
ArriVent BioPharma	N/A	-50.26%	-46.66%

Summary

Xenon Pharmaceuticals beats ArriVent BioPharma on 8 of the 15 factors compared between the two stocks.

How does ArriVent BioPharma compare to PTC Therapeutics?

ArriVent BioPharma (NASDAQ:AVBP) and PTC Therapeutics (NASDAQ:PTCT) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

PTC Therapeutics has higher revenue and earnings than ArriVent BioPharma. PTC Therapeutics is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.62	N/A
PTC Therapeutics	$1.73B	3.41	$682.64M	-$0.58	N/A

ArriVent BioPharma has a net margin of 0.00% compared to PTC Therapeutics' net margin of -3.80%. ArriVent BioPharma's return on equity of -50.26% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ArriVent BioPharma	N/A	-50.26%	-46.66%
PTC Therapeutics	-3.80%	-362.45%	-1.32%

9.5% of ArriVent BioPharma shares are owned by institutional investors. 8.6% of ArriVent BioPharma shares are owned by insiders. Comparatively, 5.3% of PTC Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

ArriVent BioPharma currently has a consensus target price of $44.86, indicating a potential upside of 47.07%. PTC Therapeutics has a consensus target price of $98.55, indicating a potential upside of 39.31%. Given ArriVent BioPharma's stronger consensus rating and higher possible upside, analysts clearly believe ArriVent BioPharma is more favorable than PTC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
PTC Therapeutics	2 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.64

In the previous week, PTC Therapeutics had 5 more articles in the media than ArriVent BioPharma. MarketBeat recorded 10 mentions for PTC Therapeutics and 5 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 1.46 beat PTC Therapeutics' score of 1.15 indicating that ArriVent BioPharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ArriVent BioPharma	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
PTC Therapeutics	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ArriVent BioPharma has a beta of 1.35, suggesting that its share price is 35% more volatile than the broader market. Comparatively, PTC Therapeutics has a beta of 0.55, suggesting that its share price is 45% less volatile than the broader market.

Summary

ArriVent BioPharma beats PTC Therapeutics on 9 of the 16 factors compared between the two stocks.

How does ArriVent BioPharma compare to Dianthus Therapeutics?

ArriVent BioPharma (NASDAQ:AVBP) and Dianthus Therapeutics (NASDAQ:DNTH) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, media sentiment, profitability, earnings and risk.

ArriVent BioPharma has a net margin of 0.00% compared to Dianthus Therapeutics' net margin of -10,096.95%. Dianthus Therapeutics' return on equity of -22.53% beat ArriVent BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ArriVent BioPharma	N/A	-50.26%	-46.66%
Dianthus Therapeutics	-10,096.95%	-22.53%	-21.55%

ArriVent BioPharma has a beta of 1.35, suggesting that its share price is 35% more volatile than the broader market. Comparatively, Dianthus Therapeutics has a beta of 1.24, suggesting that its share price is 24% more volatile than the broader market.

ArriVent BioPharma presently has a consensus target price of $44.86, suggesting a potential upside of 47.07%. Dianthus Therapeutics has a consensus target price of $124.27, suggesting a potential upside of 15.18%. Given ArriVent BioPharma's higher possible upside, equities research analysts plainly believe ArriVent BioPharma is more favorable than Dianthus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.93

9.5% of ArriVent BioPharma shares are held by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are held by institutional investors. 8.6% of ArriVent BioPharma shares are held by company insiders. Comparatively, 3.0% of Dianthus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Dianthus Therapeutics has higher revenue and earnings than ArriVent BioPharma. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.62	N/A
Dianthus Therapeutics	$2.04M	2,891.35	-$162.34M	-$4.15	N/A

In the previous week, Dianthus Therapeutics had 5 more articles in the media than ArriVent BioPharma. MarketBeat recorded 10 mentions for Dianthus Therapeutics and 5 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 1.46 beat Dianthus Therapeutics' score of 1.34 indicating that ArriVent BioPharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ArriVent BioPharma	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Dianthus Therapeutics	7 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Dianthus Therapeutics beats ArriVent BioPharma on 9 of the 16 factors compared between the two stocks.

How does ArriVent BioPharma compare to Ligand Pharmaceuticals?

Ligand Pharmaceuticals (NASDAQ:LGND) and ArriVent BioPharma (NASDAQ:AVBP) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings, media sentiment and analyst recommendations.

Ligand Pharmaceuticals has a net margin of 67.88% compared to ArriVent BioPharma's net margin of 0.00%. Ligand Pharmaceuticals' return on equity of 20.06% beat ArriVent BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ligand Pharmaceuticals	67.88%	20.06%	11.68%
ArriVent BioPharma	N/A	-50.26%	-46.66%

Ligand Pharmaceuticals has higher revenue and earnings than ArriVent BioPharma. ArriVent BioPharma is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ligand Pharmaceuticals	$290.54M	19.60	$124.45M	$9.35	30.56
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.62	N/A

In the previous week, ArriVent BioPharma had 2 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 5 mentions for ArriVent BioPharma and 3 mentions for Ligand Pharmaceuticals. ArriVent BioPharma's average media sentiment score of 1.46 beat Ligand Pharmaceuticals' score of 0.90 indicating that ArriVent BioPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ligand Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ArriVent BioPharma	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are owned by institutional investors. 5.6% of Ligand Pharmaceuticals shares are owned by company insiders. Comparatively, 8.6% of ArriVent BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Ligand Pharmaceuticals has a beta of 1.11, indicating that its stock price is 11% more volatile than the broader market. Comparatively, ArriVent BioPharma has a beta of 1.35, indicating that its stock price is 35% more volatile than the broader market.

Ligand Pharmaceuticals currently has a consensus price target of $335.75, suggesting a potential upside of 17.52%. ArriVent BioPharma has a consensus price target of $44.86, suggesting a potential upside of 47.07%. Given ArriVent BioPharma's higher probable upside, analysts clearly believe ArriVent BioPharma is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ligand Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	3.00
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Summary

Ligand Pharmaceuticals beats ArriVent BioPharma on 10 of the 15 factors compared between the two stocks.

How does ArriVent BioPharma compare to CRISPR Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and ArriVent BioPharma (NASDAQ:AVBP) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.

CRISPR Therapeutics has a beta of 1.76, suggesting that its stock price is 76% more volatile than the broader market. Comparatively, ArriVent BioPharma has a beta of 1.35, suggesting that its stock price is 35% more volatile than the broader market.

CRISPR Therapeutics presently has a consensus price target of $68.06, suggesting a potential upside of 21.27%. ArriVent BioPharma has a consensus price target of $44.86, suggesting a potential upside of 47.07%. Given ArriVent BioPharma's stronger consensus rating and higher possible upside, analysts clearly believe ArriVent BioPharma is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	1 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.61
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

ArriVent BioPharma has lower revenue, but higher earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51M	1,545.94	-$581.60M	-$4.76	N/A
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.62	N/A

ArriVent BioPharma has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -3,368.72%. CRISPR Therapeutics' return on equity of -24.39% beat ArriVent BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-3,368.72%	-24.39%	-18.25%
ArriVent BioPharma	N/A	-50.26%	-46.66%

69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are held by institutional investors. 5.2% of CRISPR Therapeutics shares are held by insiders. Comparatively, 8.6% of ArriVent BioPharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, CRISPR Therapeutics had 8 more articles in the media than ArriVent BioPharma. MarketBeat recorded 13 mentions for CRISPR Therapeutics and 5 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 1.46 beat CRISPR Therapeutics' score of 0.36 indicating that ArriVent BioPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	1 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
ArriVent BioPharma	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

CRISPR Therapeutics and ArriVent BioPharma tied by winning 8 of the 16 factors compared between the two stocks.

Get ArriVent BioPharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AVBP vs. The Competition

Export

Metric	ArriVent BioPharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.50B	$4.01B	$7.25B	$12.92B
Dividend Yield	N/A	3.61%	2.53%	8.56%
P/E Ratio	-8.43	12.72	273.84	25.43
Price / Sales	N/A	1,360.78	675.54	123.68
Price / Cash	N/A	105.29	76.98	52.08
Price / Book	4.10	16.27	12.90	6.17
Net Income	-$166.31M	-$22.72M	$3.48B	$349.24M
7 Day Performance	-1.61%	-1.72%	-0.42%	-1.46%
1 Month Performance	2.90%	10.75%	6.41%	2.47%
1 Year Performance	58.52%	53.10%	24.92%	15.80%

ArriVent BioPharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AVBP ArriVent BioPharma	2.5502 of 5 stars	$30.37 -0.5%	$44.86 +47.7%	+53.8%	$1.50B	N/A	N/A	40	Positive News
XENE Xenon Pharmaceuticals	2.5476 of 5 stars	$60.00 -0.4%	$77.13 +28.6%	+53.1%	$5.82B	N/A	N/A	210	Positive News Insider Trade
PTCT PTC Therapeutics	3.7623 of 5 stars	$70.56 +1.5%	$98.55 +39.7%	+36.9%	$5.80B	$1.73B	N/A	1,410	Analyst Upgrade
DNTH Dianthus Therapeutics	2.2057 of 5 stars	$106.62 +1.0%	$124.27 +16.6%	+345.5%	$5.77B	$1.90M	N/A	80	Positive News
LGND Ligand Pharmaceuticals	3.895 of 5 stars	$284.27 +0.1%	$335.75 +18.1%	+75.2%	$5.66B	$268.09M	30.40	80

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AVBP) was last updated on 9/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ArriVent BioPharma (AVBP) Competitors

AVBP vs. XENE, PTCT, DNTH, LGND, and CRSP

How does ArriVent BioPharma compare to Xenon Pharmaceuticals?

Summary

How does ArriVent BioPharma compare to PTC Therapeutics?

Summary

How does ArriVent BioPharma compare to Dianthus Therapeutics?

Summary

How does ArriVent BioPharma compare to Ligand Pharmaceuticals?

Summary

How does ArriVent BioPharma compare to CRISPR Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVBP vs. The Competition

ArriVent BioPharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ArriVent BioPharma (AVBP) Competitors

AVBP vs. XENE, PTCT, DNTH, LGND, and CRSP

How does ArriVent BioPharma compare to Xenon Pharmaceuticals?

Do insiders and institutionals hold more shares of XENE or AVBP?

Which has more risk and volatility, XENE or AVBP?

Does the media refer more to XENE or AVBP?

Do analysts prefer XENE or AVBP?

Which has higher valuation & earnings, XENE or AVBP?

Is XENE or AVBP more profitable?

Summary

How does ArriVent BioPharma compare to PTC Therapeutics?

Which has better valuation and earnings, AVBP or PTCT?

Is AVBP or PTCT more profitable?

Do insiders & institutionals believe in AVBP or PTCT?

Do analysts rate AVBP or PTCT?

Does the media prefer AVBP or PTCT?

Which has more risk and volatility, AVBP or PTCT?

Summary

How does ArriVent BioPharma compare to Dianthus Therapeutics?

Is AVBP or DNTH more profitable?

Which has more volatility and risk, AVBP or DNTH?

Do analysts recommend AVBP or DNTH?

Do insiders and institutionals believe in AVBP or DNTH?

Which has higher earnings and valuation, AVBP or DNTH?

Does the media prefer AVBP or DNTH?

Summary

How does ArriVent BioPharma compare to Ligand Pharmaceuticals?

Is LGND or AVBP more profitable?

Which has higher valuation and earnings, LGND or AVBP?

Does the media refer more to LGND or AVBP?

Do institutionals and insiders hold more shares of LGND or AVBP?

Which has more risk and volatility, LGND or AVBP?

Do analysts prefer LGND or AVBP?

Summary

How does ArriVent BioPharma compare to CRISPR Therapeutics?

Which has more volatility & risk, CRSP or AVBP?

Do analysts prefer CRSP or AVBP?

Which has preferable valuation & earnings, CRSP or AVBP?

Is CRSP or AVBP more profitable?

Do institutionals and insiders hold more shares of CRSP or AVBP?

Does the media favor CRSP or AVBP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVBP vs. The Competition

ArriVent BioPharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools